Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 10
Submit an article Journal homepage
314
Views
18
CrossRef citations to date
0
Altmetric
Editorial

Glutamate hypothesis of depression and its consequences for antidepressant treatments

Laura Musazzi Laboratory of Neuropsychopharmacology and Functional Neurogenomics – Department of Pharmacological and Biomolecular Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Milano, Italy
,
Giulia Treccani Laboratory of Neuropsychopharmacology and Functional Neurogenomics – Department of Pharmacological and Biomolecular Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Milano, Italy
&
Maurizio Popoli Laboratory of Neuropsychopharmacology and Functional Neurogenomics – Department of Pharmacological and Biomolecular Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Milano, Italy. [email protected]
Pages 1169-1172 | Published online: 09 Jan 2014

References

  • Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11), e442 (2006).
  • Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 455(7215), 894–902 (2008).
  • Racagni G, Popoli M. The pharmacological properties of antidepressants. Int. Clin. Psychopharmacol. 25(3), 117–131 (2010).
  • Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62(1), 63–77 (2012).
  • Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 62(11), 1310–1316 (2007).
  • Küçükibrahimoglu E, Saygin MZ, Caliskan M, Kaplan OK, Unsal C, Gören MZ. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur. J. Clin. Pharmacol. 65(6), 571–577 (2009).
  • Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 68(9), 785–794 (2010).
  • Zhang J, Narr KL, Woods RP, Phillips OR, Alger JR, Espinoza RT. Glutamate normalization with ECT treatment response in major depression. Mol. Psychiatry doi:10.1038/mp.2012.46 (2012) (Epub ahead of print).
  • Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32(9), 1888–1902 (2007).
  • Choudary PV, Molnar M, Evans SJ et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl Acad. Sci. USA 102(43), 15653–15658 (2005).
  • Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets 6(3), 219–233 (2007).
  • Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum. Brain Mapp. 30(11), 3719–3735 (2009).
  • Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13(1), 22–37 (2012).
  • Olijslagers JE, de Kloet ER, Elgersma Y, van Woerden GM, Joëls M, Karst H. Rapid changes in hippocampal CA1 pyramidal cell function via pre- as well as postsynaptic membrane mineralocorticoid receptors. Eur. J. Neurosci. 27(10), 2542–2550 (2008).
  • Musazzi L, Milanese M, Farisello P et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS ONE 5(1), e8566 (2010).
  • Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33(1), 88–109 (2008).
  • McCarthy DJ, Alexander R, Smith MA et al. Glutamate-based depression GBD. Med. Hypotheses 78(5), 675–681 (2012).
  • Zarate CA Jr, Singh JB, Carlson PJet al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63(8), 856–864 (2006).
  • Valentine GW, Mason GF, Gomez R et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 191(2), 122–127 (2011).
  • Krystal JH, Mathew SJ, D’Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24(8), 669–693 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.